ClinicalTrials.gg
RecruitingNCT07419334NORTHSTARUpdated Sep 18, 2026

Study of ALK-001 on the Progression of Stargardt Disease

A Phase 3 interventional study of ALK-001 and Placebo in Stargardt Disease, sponsored by Alkeus Pharmaceuticals, Inc.. Recruiting at 14 sites in United States. Open to participants aged 8 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Alkeus Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
8 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Planned enrollment
3rd of 26
230 · median 41
Started
2026
with 5 others
Phase 3
3 of 42
1 open now
Primary completion
2029-10
later than 18 of 24 live
Registered
38th of 42
by date
Lead sponsor
3 of 42
Alkeus Pharmaceuticals, Inc.

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 3rd largest by planned enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 in phase 3, reaches primary completion later than 18 of the 24 other live ones, and was the 38th registered.

Stargardt Disease

66 studies on the registry are indexed under Stargardt Disease; 25 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Stargardt Disease studies recruiting now, 14 (64%) set no upper age limit and 7 (32%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 8 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)

03

Conditions studied

  • Stargardt Disease

Browse trials for

Keywords

  • Stargardt Macular Degeneration
  • Stargardt Macular Dystrophy
  • Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
04

Who can participate

Ages eligible
8 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 8 to 45 years of age (inclusive) on the day of screening.
  2. Female participants of , as well as fertile male participants with female partners of childbearing potential, must be willing to comply with the protocol-defined methods of from the time of consent until 90 days and 30 days, respectively, after the last dose of IMP.
  3. Have a clinical diagnosis of typical autosomal recessive STGD macular dystrophy
  4. Have provided a genetic report by any regional accredited organization that provides certified testing indicating the presence of disease-causing mutation.
  5. Have signed and dated the forms (ICFs; or assent as appropriate) to participate.

Exclusion criteria

Exclusion Criteria

  1. Has taken disallowed items (supplements containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) within 30 days of randomization.
  2. Is lactating, pregnant, or has a positive serum or urine pregnancy test at screening or at randomization, or is planning to become pregnant during the course of study. A male participant who wishes to father a child during the course of the study.
  3. Has ever participated in any gene therapy, cell therapy, or device study to treat STGD, unless documented confirmation of participation in the placebo arm with no surgery is provided. Has participated in a drug study to treat STGD within the past 6 months.
  4. Has participated in any drug study to treat any other condition within 5 half-lives of the drug prior to screening, unless documented confirmation of participation in the placebo arm is provided. Has participated in an investigational device study within 30 days prior to screening or longer if, in the Investigator's judgment, the device could affect study outcomes.
  5. Anticipates participating in any other drug or device study within the duration of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Active comparator
    Active

    Drug: ALK-001

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Daily oral administration for 24 months

    Also known as: Gildeuretinol acetate

  • DrugPlacebo

    Daily oral administration for 24 months

06

What researchers measure

Primary outcomes

  1. Annualized growth rate of retinal atrophic lesions measured by Fundus Autofluorescence

    Annualized growth rate of retinal atrophic lesions measured by Fundus Autofluorescence

    Time frame: Month 6 to Month 24

Secondary outcomes

  1. Changes in Low Luminance Visual Acuity from baseline to Month 24

    Changes in Low Luminance Visual Acuity from baseline to Month 24

    Time frame: baseline to Month 24

07

Study locations

12 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Oct 2029, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 19, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Oct 2029
CompletionEst.
Dec 2030
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07419334
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Jun 3, 2026
Primary completion
Oct 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Sep 18, 2026

Study contacts

For trial questions: trials@alkeuspharma.com or 877-255-7476
Contact
trials@alkeuspharma.com
877-255-7476

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gildeuretinol acetate

Start the discussion